Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 7/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | MC4R | P32245 | 5/20 | 0.33 |
| ▸ | MC3R | P41968 | 5/20 | 0.33 |
| ▸ | MC1R | Q01726 | 5/20 | 0.33 |
| ▸ | CCKBR | P32239 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4372111 | 1.00 | GHSR (0.42) | GHSROPRD1DPP4MC4RMC3R | |
| SCHEMBL4372106 | 1.00 | GHSR (0.42) | GHSROPRD1DPP4MC4RMC3R | |
| SCHEMBL868493 | 0.90 | GHSR (0.37) | GHSROPRD1DPP4CCKBR | |
| SCHEMBL868492 | 0.90 | GHSR (0.37) | GHSROPRD1DPP4CCKBR | |
| SCHEMBL7860577 | 0.89 | MEN1 (0.43) | GHSROPRD1 | |
| SCHEMBL868237 | 0.89 | MEN1 (0.43) | GHSROPRD1 | |
| SCHEMBL868238 | 0.89 | MEN1 (0.43) | GHSROPRD1 | |
| SCHEMBL4385374 | 0.88 | GHSR (0.40) | GHSROPRD1DPP4MC4RMC3R | |
| SCHEMBL866895 | 0.88 | GHSR (0.53) | GHSROPRD1DPP4CCKBR | |
| SCHEMBL866894 | 0.88 | GHSR (0.53) | GHSROPRD1DPP4CCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1077941-B1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK AS (DK) | 2009-08-12 | — | — | EP | claimed |
| US-6303620-B1 | USED FOR THERAPY OF MEDICAL DISORDERS RESULTING FROM A DEFICIENCY IN GROWTH HORMONE | NOVO NORDISK A/S (DK) | 2001-10-16 | — | — | US | claimed |
| EP-1077941-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | Novo Nordisk A/S (DK) | 2001-02-28 | — | — | EP | claimed |
| WO-1999058501-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1999-11-18 | — | — | WO | claimed |
| US-8394833-B2 | Methods of treating emesis using growth hormone secretagogues | HELSINN THERAPEUTICS (U.S.), INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-8288427-B2 | Methods of treating emesis using growth hormone secretagogues | HELSINN THERAPEUTICS (U.S.), INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20120232113-A1 | METHODS OF TREATING EMESIS USING GROWTH HORMONE SECRETAGOGUES | HELSINN THERAPEUTICS (U.S.), INC. (US) | 2012-09-13 | — | — | US | disclosed |
| US-20120077745-A1 | Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues | HELSINN THERAPEUTICS (U.S.), INC. (US) | 2012-03-29 | — | — | US | disclosed |
| US-8039457-B2 | Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues | HELSINN THERAPEUTICS (U.S.), INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-20100087381-A1 | Method of Stimulating the Motility of the Gastrointestinal System Using Growth Hormone Secretagogues | HELSINN THERAPEUTICS (U.S.), INC. (US) | 2010-04-08 | — | — | US | disclosed |
| US-20080300194-A1 | Methods of treating emesis using growth hormone secretagogues | SAPPHIRE THERAPEUTICS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-20080207640-A1 | Method of treating cell proliferative disorders using growth hormone secretagogues | SAPPHIRE THERAPEUTICS (US) | 2008-08-28 | — | — | US | disclosed |
| US-20070191283-A1 | Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues | REJUVENON CORPORATION | 2007-08-16 | — | — | US | disclosed |
| US-20050261201-A1 | Method of reducing C-reactive protein using growth hormone secretagogues | REJUVENON CORPORATION (US) | 2005-11-24 | — | — | US | disclosed |
| US-6303620-B1 | USED FOR THERAPY OF MEDICAL DISORDERS RESULTING FROM A DEFICIENCY IN GROWTH HORMONE | NOVO NORDISK A/S (DK) | 2001-10-16 | — | — | US | disclosed |
| EP-1077941-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | Novo Nordisk A/S (DK) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999058501-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1999-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261201-A1 | Method of reducing C-reactive protein using growth hormone secretagogues | CETP, FABP7, TGFB1 | GHSR 14/4885OPRD1 3955/4885DPP4 436/4885 |
| US-20120077745-A1 | Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues | GHSR, GHRHR, MLNR | GHSR 1/4885OPRD1 57/4885DPP4 153/4885 |
| US-20120232113-A1 | METHODS OF TREATING EMESIS USING GROWTH HORMONE SECRETAGOGUES | GHSR, GHRHR, CRH | GHSR 1/4885OPRD1 3939/4885DPP4 216/4885 |
| US-20080300194-A1 | Methods of treating emesis using growth hormone secretagogues | GHSR, GHRHR, CRH | GHSR 1/4885OPRD1 3939/4885DPP4 216/4885 |
| US-20100087381-A1 | Method of Stimulating the Motility of the Gastrointestinal System Using Growth Hormone Secretagogues | GHSR, GHRHR, MLNR | GHSR 1/4885OPRD1 57/4885DPP4 153/4885 |
| US-20080207640-A1 | Method of treating cell proliferative disorders using growth hormone secretagogues | GHSR, GHRHR, SSTR5 | GHSR 1/4885OPRD1 4711/4885DPP4 586/4885 |
| US-20070191283-A1 | Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues | GHSR, GHRHR, MLNR | GHSR 1/4885OPRD1 57/4885DPP4 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.